期刊文献+
共找到5篇文章
< 1 >
每页显示 20 50 100
多模式磁共振指导下尿激酶与阿替普酶溶栓疗效比较及安全性观察 被引量:2
1
作者 张再辉 《中国冶金工业医学杂志》 2019年第1期97-98,共2页
急性脑梗死是最常见的卒中类型,溶栓仍为现阶段治疗急性脑梗死的主要方式,而尿激酶及阿替普酶作为溶栓的第一代及第二代药物在临床中应用广泛[1]。尿激酶因其价格低廉,更符合我国国情。阿替普酶于体内可直接激活纤溶酶原转化为纤溶酶,... 急性脑梗死是最常见的卒中类型,溶栓仍为现阶段治疗急性脑梗死的主要方式,而尿激酶及阿替普酶作为溶栓的第一代及第二代药物在临床中应用广泛[1]。尿激酶因其价格低廉,更符合我国国情。阿替普酶于体内可直接激活纤溶酶原转化为纤溶酶,且不增加全身性纤溶亢进,但价格高昂,且仍可导致脑出血等不良反应,临床使用受限[2]。本研究以78例急性脑梗死为对象,剖析阿替普酶及尿激酶溶栓后的溶栓疗效及安全性. 展开更多
关键词 阿替普酶 尿激酶组 不良反应 尿激酶 溶栓疗效 磁共振
原文传递
Small gastrointestinal stromal tumor concomitant with early gastric cancer:A case report 被引量:18
2
作者 Ying-Lung Lin Jeh-En Tzeng Chih-Wen Lin 《World Journal of Gastroenterology》 SCIE CAS CSCD 2006年第5期815-817,共3页
The term gastrointestinal stromal tumors (GISTs) is defined diagnostically as the main group of mesenchymal tumors with spindle or epithelioid cells arising from the wall of the gastrointestinal tract with immunohis... The term gastrointestinal stromal tumors (GISTs) is defined diagnostically as the main group of mesenchymal tumors with spindle or epithelioid cells arising from the wall of the gastrointestinal tract with immunohistochemical reactivity for CD117 antibody. Previous studies revealed that cells in GISTs express a growth factor receptor with tyrosine kinase activity (termed c-kit), which is the product of the c-kit protooncogene. The most specific and practical diagnostic criteria for GISTs are: immunohistochemically determined c-kit (CD117) expression; mitotic score; and tumor size. A small GIST concomitant with early gastric cancer is rarely encountered clinically. Herein we have reported a case of a 1.1-cm GIST detected by esophagogastroduo denoscopy concomitant with a IIc type of early gastric cancer (signet ring cell type). It was detected during a routine physical health examination. To our knowledge, this is the first report of a small GIST concomitant with a signet ring cell type of early gastric cancer. 展开更多
关键词 Gastrointestinal stromal tumor Early gastriccancer Npylori infection Biopsy urease test CD117
下载PDF
Immunoprotection of A Recombinant Attenuated Salmonella Typhimurium Vaccine Strain Expressing Helicobacter pylori Urease Subunit B to Mice against Helicobacter pylori Infection
3
作者 ZhuSen-lin ChenMin-hu LiaoWen-jun ChenJie HuPin-jin 《胃肠病学》 2000年第B08期109-110,共2页
关键词 免疫反应 细胞 沙门氏菌属 疫苗 基因表达 幽门螺杆菌 尿激酶组B 老鼠 传染病
全文增补中
In vitro renaturation of recombinant human pro-urokinase expressed in Escherichia coli 被引量:1
4
作者 朱慧 刘伟 +3 位作者 史蔚 薛宇鸣 蒯乐天 马忠 《Chinese Medical Journal》 SCIE CAS CSCD 2001年第2期74-78,110,共6页
Objective Recombinant human pro-urokinase forms insoluble inclusion body when overexpressed in Escherichia coli. It must be denatured and renatured in vitro so that it can acquire activity. This study aimed at increa... Objective Recombinant human pro-urokinase forms insoluble inclusion body when overexpressed in Escherichia coli. It must be denatured and renatured in vitro so that it can acquire activity. This study aimed at increasing the renaturation yield of denaturant pro-urokinase. Methods We evaluated the basic renaturation conditions of pro-urokinase through qualitative and quantitative analysis of pH, temperature, denatured concentration, protein concentration, and the ratio of reduced and oxidized thiol reagents. We also compared the effects of nonspecific additives, step-wise dilution and urea gradient dialysis.Results We defined the optimal conditions of pro-urokinase renaturation with a yield of about 20%-30%. Conclusion Different recombinant denatured proteins have different renaturation conditions due to their different molecular sizes, molecular constructions, disulfide bond numbers, and hydrophobicity. The renaturation yield can be increased by optimizing the renaturation conditions of a specific protein. 展开更多
关键词 recombinant human pro urokinase · denaturation · renaturation
原文传递
Clinical significance of plasma tissue factor pathway and urokinase-type plasminogen activator system in cancer patients 被引量:1
5
作者 赵维莅 王学锋 +2 位作者 璩斌 黄霞萍 王鸿利 《Chinese Medical Journal》 SCIE CAS CSCD 2002年第5期702-704,150,共3页
OBJECTIVE: To evaluate variations in the plasma tissue factor (TF) and urokinase type plasminogen activator (u-PA) system and their relationship with clinical cancer type, pathological classification and metastatic st... OBJECTIVE: To evaluate variations in the plasma tissue factor (TF) and urokinase type plasminogen activator (u-PA) system and their relationship with clinical cancer type, pathological classification and metastatic status in cancer patients. METHODS: Plasma levels of TF and its inhibitor (TFPI), as well as u-PA and its receptor (u-PAR) were measured using ELISA in 76 patients with malignant tumors and 24 patients with benign tumors. RESULTS: Plasma levels of TF and u-PAR in the malignant tumor group were significantly higher than those of the benign tumor group and the normal control. U-PA and u-PAR increased significantly in patients with esophageal and gastric cancer. However, most of these parameters except TFPI did not vary according to pathological classification. A significant elevation was evident in patients with local infiltration, lymph node involvement and distal metastasis, while u-PAR only increased in the latter two categories. CONCLUSIONS: Both the TF and u-PA systems are activated in cancer patients. U-PA and its receptor might prove to be a clinically useful marker for disease progression. 展开更多
关键词 ADULT Aged Aged 80 and over Female Humans LIPOPROTEINS Male Middle Aged Neoplasm Metastasis NEOPLASMS Receptors Cell Surface Research Support Non-U.S. Gov't THROMBOPLASTIN Urinary Plasminogen Activator
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部